CN101065152A - 靶向尿激酶纤溶酶原激活物受体的造影剂 - Google Patents

靶向尿激酶纤溶酶原激活物受体的造影剂 Download PDF

Info

Publication number
CN101065152A
CN101065152A CNA2005800408838A CN200580040883A CN101065152A CN 101065152 A CN101065152 A CN 101065152A CN A2005800408838 A CNA2005800408838 A CN A2005800408838A CN 200580040883 A CN200580040883 A CN 200580040883A CN 101065152 A CN101065152 A CN 101065152A
Authority
CN
China
Prior art keywords
contrast agent
agent according
ser
trp
moiety
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2005800408838A
Other languages
English (en)
Chinese (zh)
Inventor
A·卡思伯森
B·E·阿波
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GE Healthcare AS
Original Assignee
GE Healthcare AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GE Healthcare AS filed Critical GE Healthcare AS
Publication of CN101065152A publication Critical patent/CN101065152A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0056—Peptides, proteins, polyamino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0032—Methine dyes, e.g. cyanine dyes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Radiology & Medical Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CNA2005800408838A 2004-09-29 2005-09-28 靶向尿激酶纤溶酶原激活物受体的造影剂 Pending CN101065152A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NO20044139 2004-09-29
NO20044139 2004-09-29

Publications (1)

Publication Number Publication Date
CN101065152A true CN101065152A (zh) 2007-10-31

Family

ID=35930012

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2005800408838A Pending CN101065152A (zh) 2004-09-29 2005-09-28 靶向尿激酶纤溶酶原激活物受体的造影剂

Country Status (11)

Country Link
US (1) US8568689B1 (enExample)
EP (1) EP1796733A2 (enExample)
JP (1) JP5122962B2 (enExample)
KR (1) KR101248350B1 (enExample)
CN (1) CN101065152A (enExample)
AU (1) AU2005287934B2 (enExample)
BR (1) BRPI0516168A (enExample)
CA (1) CA2580464A1 (enExample)
MX (1) MX2007003750A (enExample)
RU (1) RU2394837C2 (enExample)
WO (1) WO2006036071A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104768573A (zh) * 2012-05-08 2015-07-08 国立医院 用于位点特异性uPAR靶向的177-Lu标记肽

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070190068A1 (en) * 2005-10-10 2007-08-16 Richard Hart uPAR-binding molecule-drug conjugates and uses thereof
US8273325B2 (en) * 2006-12-20 2012-09-25 Ge Healthcare As Contrast agents
GB0718967D0 (en) * 2007-09-28 2007-11-07 Ge Healthcare Ltd Peptide imaging agents
GB0718957D0 (en) * 2007-09-28 2007-11-07 Ge Healthcare Ltd Optical imaging agents
DK2598175T3 (da) * 2010-07-27 2020-08-03 Serac Healthcare Ltd Radiofarmaceutiske sammensætninger
US9884131B2 (en) * 2012-12-03 2018-02-06 Curasight Aps Positron emitting radionuclide labeled peptides for human uPAR PET imaging
US20210138090A1 (en) * 2014-09-17 2021-05-13 Fluoguide A/S uPAR targeting peptide for use in peroperative optical imaging of invasive cancer
AU2015317444B2 (en) * 2014-09-17 2020-07-16 Fluoguide A/S uPAR targeting peptide for use in peroperative optical imaging of invasive cancer
RU2720976C2 (ru) * 2015-06-03 2020-05-15 Сюржимаб С.А.С. Флуоресцентные конъюгаты и их применение для диагностики опухоли
US11970554B2 (en) 2018-03-01 2024-04-30 Tonix Pharmaceuticals Holding Corp. Labeled oxytocin and method of manufacture and use
WO2021009219A1 (en) * 2019-07-16 2021-01-21 Fluoguide A/S A receptor-targeting conjugate with an effective pharmacokinetic profile
BR112022000164A2 (pt) * 2019-07-16 2022-04-12 Fluoguide As Conjugado de peptídeo direcionado a receptor de ativador de uroquinase-plasminogênio, composição farmacêutica, métodos para imageamento óptico e para detecção de uma doença, uso do conjugado de peptídeo ou da composição farmacêutica, e, kit de peças para a preparação de uma dosagem unitária
CN117412777A (zh) * 2020-12-01 2024-01-16 库拉赛特股份公司 尿激酶纤溶酶原活化剂受体靶向的放射性标记的肽缀合物
EP4277666A1 (en) * 2021-01-15 2023-11-22 Fluoguide A/S A upar (urokinase plasminogen activator receptor)-targeting conjugate

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6120765A (en) * 1993-04-02 2000-09-19 Shiseido Co. Ltd. Urokinase plasminogen activator fragments
US6277818B1 (en) * 1998-10-29 2001-08-21 Angstrom Pharmaceuticals, Inc. Cyclic peptide ligands that target urokinase plasminogen activator receptor
US5942492A (en) * 1996-11-12 1999-08-24 Angstrom Pharmaceuticals, Inc. Cyclic peptides that bind to urokinase-type plasminogen activator receptor
GB9705521D0 (en) 1997-03-18 1997-05-07 Univ Sheffield The use of mononuclear phagocytes in the vivo imaging of hypoxic/ischaemic tissue
AR020101A1 (es) * 1998-07-01 2002-04-10 Cancerforskingsfonden Af 1989 Un antagonista peptido del receptor de uroquinasa humana, composicion farmaceutica que lo contiene, su uso para la manufactura de un medicamento y metodopara seleccionar un antagonista peptido adecuado.
US6896870B1 (en) * 1999-10-01 2005-05-24 Angstrom Pharmaceuticals, Inc. Diagnostic probes and therapeutics targeting uPA and uPAR
AU780730B2 (en) * 1999-10-01 2005-04-14 Angstrom Pharmaceuticals, Inc. Diagnostic probes and therapeutics targeting uPA and uPAR
RU2165266C1 (ru) * 2000-06-28 2001-04-20 Центральный научно-исследовательский рентгенорадиологический институт Способ получения [2-18f]-2-дезоксиглюкозы
US7763234B2 (en) 2004-03-04 2010-07-27 Ge Healthcare As Pharmaceutical compounds

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104768573A (zh) * 2012-05-08 2015-07-08 国立医院 用于位点特异性uPAR靶向的177-Lu标记肽
CN104768573B (zh) * 2012-05-08 2017-08-29 Trt创新有限责任公司 用于位点特异性uPAR靶向的177‑Lu标记肽

Also Published As

Publication number Publication date
KR20070083604A (ko) 2007-08-24
AU2005287934A1 (en) 2006-04-06
JP2008514588A (ja) 2008-05-08
WO2006036071A3 (en) 2007-02-15
MX2007003750A (es) 2007-11-07
JP5122962B2 (ja) 2013-01-16
KR101248350B1 (ko) 2013-04-01
RU2007111467A (ru) 2008-11-10
EP1796733A2 (en) 2007-06-20
CA2580464A1 (en) 2006-04-06
BRPI0516168A (pt) 2008-08-26
US8568689B1 (en) 2013-10-29
RU2394837C2 (ru) 2010-07-20
WO2006036071A2 (en) 2006-04-06
AU2005287934B2 (en) 2009-03-26

Similar Documents

Publication Publication Date Title
CN1230441C (zh) 结合整联蛋白的肽衍生物
CN1093424C (zh) 含单胺、联氨、硫羟基的金属螯合剂
CN1738650A (zh) 改进的胃泌素释放肽化合物
CN103533963B (zh) 用通过nota络合的[18]氟化铝标记的her2结合肽
CN1622830A (zh) 肽基化合物
CN101065152A (zh) 靶向尿激酶纤溶酶原激活物受体的造影剂
CN1599577A (zh) 肽基多聚体靶向的造影介质
JP7667765B2 (ja) がんイメージング及びがん放射線治療のための組成物及び方法
CN103402550B (zh) 用含有18f的有机硅化合物标记的her2结合肽
CN1503680A (zh) 用于金属放射性药物的抗坏血酸类似物
CN1968963A (zh) 基于肽的化合物
CN1527727A (zh) 改进的螯合剂共轭物
EP3412303A1 (en) Improved pharmacokinetics and cholecystokinin-2 receptor (cck2r) targeting for diagnosis and therapy
CN1738652A (zh) 用于药物化合物的改进的接头
US9061080B2 (en) HER2 binding peptides labeled with aluminium-[18] fluoride complexed by NOTA
CN1901941A (zh) 血管紧张素ii与成像部分的缀合物
CN1571680A (zh) Pacap组合物及用于肿瘤成像与治疗的方法
CN101039702A (zh) 作为靶向试剂用于内皮－特异性体内转导的热激蛋白
US20240091390A1 (en) Improved cholecystokinin-2 receptor (cck2r) targeting for diagnosis and therapy
HK1107102A (en) Peptide-based compounds
CN1897980A (zh) 改进的胃泌素释放肽化合物
HK1193987A (en) Her2 binding peptides labeled with aluminium-[18] fluoride complexed by nota
HK1191244A (en) Her2 binding peptides labelled with a 18f - containing organosilicon compound

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Open date: 20071031